As for the secondary clinical endpoint (CRP), which indicates the inflammatory status of the body, the treatment group demonstrated a more rapid normalization of the elevated CRP levels, which favors a low incidence of COVID-19 complications [57]. The gene discussed is CRP; the disease is COVID-19.